Geratherm Medical AG (GME) Fair Value & Analysis
Healthcare · DE · Market cap €15.2M
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from €4.82 to €5.05 (+4.8%) since Jun 23, 2026. Share price −2.9% over the past month.
Price vs Fair Value (12 months)
12‑month range €2.54 – €7.01 · fair‑value band €3.78 – €6.32 · the €2.73 price screens below the €5.05 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Geratherm Medical AG (GME) currently trades at €2.73, while our model-based Fair Value estimate is €5.05 — implying the stock looks roughly 85.0% undervalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Geratherm Medical AG generated revenue of €14.3M at a net margin of 12.3%. Revenue declined 3.7% year over year. It earns a return on equity of 8.6%. The balance sheet holds a net cash position of €4.4M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Geratherm Medical AG operates as a medical technology company in Germany. It operates through Healthcare Diagnostic, Respiratory, Cardio/Stroke, and Medical Warming Systems segments. The Healthcare Diagnostic segment provides clinical thermometers; and blood pressure monitors. The Respiratory segment develops and manufactures products primarily for pulmonary and cardiopulmonary function diagnostics. The Medical Warming Systems segment offers MRI-compatible incubators for premature babies under the LMT brand. The Cardio/Stroke segment offers stroke risk analysis products for the detection of atrial fibrillation. The company markets its products through pharmacies, hospitals, and clinics. It exports its products to approximately 60 countries. The company was founded in 1990 and is headquartered in Geschwenda, Germany.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Geratherm Medical AG reported revenue of €20.4M in FY2024 versus €27.5M in FY2020, a compound −7.1%/yr. Reported net income was €705K in FY2024, compounding −23.4%/yr from FY2020.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,228 MXN | -23% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Geratherm Medical AG (GME) undervalued?
What is the fair value of GME?
What is the quality score of GME?
What is the revenue of Geratherm Medical AG (GME)?
What is the net profit margin of GME?
Does Geratherm Medical AG pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.